Historique
Bulletin de Périodique
Drug Testing and Analysis , Vol.10, n°1 - January 2018
Paru le :
01/01/2018
Année
2018
Page(s) :
1-236
Langue(s) :
Anglais
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Note de contenu :
SELECTION :
- Annual banned-substance review: Analytical approaches in human sports drug testing. Thevis M., Kuuranne T., Geyer H.C.D.T.A., p. 9-27.
- The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Manchester K.R., Lomas E.C., Waters L., Dempsey F.C., Maskell P.D., p. 37-53.
- Confirmation of recent heroin abuse: Accepting the challenge. Maas A., Madea B., Hess C., p. 54-71.
- MDA, MDMA, and other "mescaline-like" substances in the US military's search for a truth drug (1940s to 1960s). Passie T., Benzenhöfer U., p. 72-80.
- A review of chemical 'spot' tests: A presumptive illicit drug identification technique. Philp M., Fu S., p. 95-108.
- Heroin in Malaysia and Singapore. Sulaiman M., Kunalan V., Yap A.T.W., Lim W.J.L., Ng J.J.Y., Loh S.W.X., et al., p. 109-119.
- Assessing the toxicological significance of new psychoactive substances in fatalities. Elliott S., Sedefov R., Evans-Brown M., p. 120-126.
- Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users. Krotulski A.J., Mohr A.L.A., Papsun D.M., Logan B.K., p. 127-136.
- Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18. Kevin R.C., Lefever T.W., Snyder R.W., Patel P.R., Gamage T.F., Fennell T.R., et al., p. 137-147.
- In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA. Staeheli S.N., Poetzsch M., Veloso V.P., Bovens M., Bissig C., Steuer A.E., et al., p. 148-157.
- Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MSn, and LC-HR-MS/MS. Caspar A.T., Gaab J.B., Michely J.A., Brandt S.D., Meyer M.R., Maurer H.H., p. 184-195.
- Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. Mogler L., Franz F., Rentsch D., Angerer V., Weinfurtner G., Longworth M., et al., p. 196-205.
- Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Huppertz L.M., Moosmann B., Auwärter V., p. 206-211.
- Determination of cannabinoid and synthetic cannabinoid metabolites in wastewater by liquid-liquid extraction and ultra-high performance supercritical fluid chromatography-tandem mass spectrometry. Gonzalez-Marino I., Thomas K.V., Reid M.J., p. 222-228.
- Identification of pyrolysis products of the new psychoactive substance 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone hydrochloride (bk-2C-B) and its iodo analogue bk-2C-I. Texter K.B., Waymach R., Kavanagh P.V., O'Brien J.E., Talbot B., Brandt S.D., et al., p. 229-236.
- Annual banned-substance review: Analytical approaches in human sports drug testing. Thevis M., Kuuranne T., Geyer H.C.D.T.A., p. 9-27.
- The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Manchester K.R., Lomas E.C., Waters L., Dempsey F.C., Maskell P.D., p. 37-53.
- Confirmation of recent heroin abuse: Accepting the challenge. Maas A., Madea B., Hess C., p. 54-71.
- MDA, MDMA, and other "mescaline-like" substances in the US military's search for a truth drug (1940s to 1960s). Passie T., Benzenhöfer U., p. 72-80.
- A review of chemical 'spot' tests: A presumptive illicit drug identification technique. Philp M., Fu S., p. 95-108.
- Heroin in Malaysia and Singapore. Sulaiman M., Kunalan V., Yap A.T.W., Lim W.J.L., Ng J.J.Y., Loh S.W.X., et al., p. 109-119.
- Assessing the toxicological significance of new psychoactive substances in fatalities. Elliott S., Sedefov R., Evans-Brown M., p. 120-126.
- Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users. Krotulski A.J., Mohr A.L.A., Papsun D.M., Logan B.K., p. 127-136.
- Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18. Kevin R.C., Lefever T.W., Snyder R.W., Patel P.R., Gamage T.F., Fennell T.R., et al., p. 137-147.
- In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA. Staeheli S.N., Poetzsch M., Veloso V.P., Bovens M., Bissig C., Steuer A.E., et al., p. 148-157.
- Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MSn, and LC-HR-MS/MS. Caspar A.T., Gaab J.B., Michely J.A., Brandt S.D., Meyer M.R., Maurer H.H., p. 184-195.
- Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. Mogler L., Franz F., Rentsch D., Angerer V., Weinfurtner G., Longworth M., et al., p. 196-205.
- Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Huppertz L.M., Moosmann B., Auwärter V., p. 206-211.
- Determination of cannabinoid and synthetic cannabinoid metabolites in wastewater by liquid-liquid extraction and ultra-high performance supercritical fluid chromatography-tandem mass spectrometry. Gonzalez-Marino I., Thomas K.V., Reid M.J., p. 222-228.
- Identification of pyrolysis products of the new psychoactive substance 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone hydrochloride (bk-2C-B) and its iodo analogue bk-2C-I. Texter K.B., Waymach R., Kavanagh P.V., O'Brien J.E., Talbot B., Brandt S.D., et al., p. 229-236.
Dépouillements
Ajouter le résultat à votre sélection
K. R. MANCHESTER ;
E. C. LOMAS ;
L. WATERS ;
F. C. DEMPSEY ;
P. D. MASKELL
|
2018
Dans Drug Testing and Analysis (Vol.10, n°1, January 2018) Article : Périodique
Dans Drug Testing and Analysis (Vol.10, n°1, January 2018) Article : Périodique
The market for new psychoactive substances has increased markedly in recent years and there is now a steady stream of compounds appearing every year. Benzodiazepines consist of only a fraction of the total number of these compounds but their use[...]
S. ELLIOTT ;
R. SEDEFOV ;
M. EVANS-BROWN
|
2018
Dans Drug Testing and Analysis (Vol.10, n°1, January 2018) Article : Périodique
Dans Drug Testing and Analysis (Vol.10, n°1, January 2018) Article : Périodique
The number of new psychoactive substances (NPS) has increased significantly, especially within the last 5 years. The EMCDDA conducts risks assessments of such substances, especially in relation to serious adverse events. Examination of the indiv[...]
I. GONZALEZ-MARINO ;
K. V. THOMAS ;
M. J. REID
|
2018
Dans Drug Testing and Analysis (Vol.10, n°1, January 2018) Article : Périodique
Dans Drug Testing and Analysis (Vol.10, n°1, January 2018) Article : Périodique
For the first time, ultra-high performance supercritical fluid chromatography (UHPSFC) coupled to tandem mass spectrometry has been used to determine cannabinoid and synthetic cannabinoid residues in wastewater. Combined with a downscaled versio[...]